| Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose H Maagensen, AE Junker, NR Jørgensen, LL Gluud, FK Knop, T Vilsbøll The Journal of Clinical Endocrinology & Metabolism 103 (5), 2042-2049, 2018 | 19 | 2018 |
| The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition S Hædersdal, A Lund, E Nielsen-Hannerup, H Maagensen, G van Hall, ... Diabetes 69 (12), 2619-2629, 2020 | 12 | 2020 |
| Liraglutide does not change bone turnover in clozapine-and olanzapine-treated schizophrenia overweight patients with prediabetes–randomized controlled trial H Maagensen, JR Larsen, NR Jørgensen, A Fink-Jensen, T Vilsbøll Psychiatry Research 296, 113670, 2021 | 9 | 2021 |
| The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes S Hædersdal, A Lund, H Maagensen, E Nielsen-Hannerup, LS Gasbjerg, ... European Journal of Endocrinology 186 (2), 207-221, 2022 | 8 | 2022 |
| The Gut-Bone Axis in Diabetes H Maagensen, MM Helsted, LS Gasbjerg, T Vilsbøll, FK Knop Current Osteoporosis Reports 21 (1), 21-31, 2023 | 4 | 2023 |
| The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes S Hædersdal, A Lund, E Nielsen-Hannerup, H Maagensen, JL Forman, ... European Journal of Endocrinology 187 (4), 507-518, 2022 | 3 | 2022 |
| Individual and combined glucose-lowering effects of glucagon receptor antagonism and sodium-glucose cotransporter 2 inhibition S Hædersdal, AB Lund, H Maagensen, E Nielsen-Hannerup, JJ Holst, ... American Diabetes Association 67 (Diabetes Supplement 1), 2018 | 3 | 2018 |
| Identification of pathogenic GCK variants in patients with common type 2 diabetes can lead to discontinuation of pharmacological treatment ACB Thuesen, RT Jensen, H Maagensen, MR Kristiansen, HT Sørensen, ... Molecular Genetics and Metabolism Reports 35, 100972, 2023 | 2 | 2023 |
| Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition S Haedersdal, AB Lund, E Nielsen-Hannerup, H Maagensen, JJ Holst, ... American Diabetes Association 67 (Diabetes Supplement 1), 2018 | 1 | 2018 |
| Glucagon Receptor Antagonism Lowers Fasting Glucose but Not Postprandial Glucose Excursions in Patients with Type 2 Diabetes S Haedersdal, A Lund, H Maagensen, E Nielsen-Hannerup, JJ Holst, ... American Diabetes Association 66 (Diabetes), A532-A532, 2017 | 1 | 2017 |
| The Role of Glucagon in Gastrointestinal-Mediated Glucose Disposal and Incretin Effect in Patients with Type 2 Diabetes and Normal Glucose Tolerant Individuals S Haedersdal, A Lund, E Nielsen-Hannerup, H Maagensen, JJ Holst, ... American Diabetes Association 66 (Diabetes), A532-A533, 2017 | 1 | 2017 |
| The role of glucagon in gastrointestinal-mediated glucose-disposal and incretin effect in patients with type 2 diabetes and normal glucose tolerant individuals E Nielsen-Hannerup, S Hædersdal, A Lund, HEG Maagensen, JJ Holst, ... 53rd Annual Meeting of the European Association for the study of Diabetes EASD, 2017 | 1 | 2017 |
| 182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3): A Case Series H MAAGENSEN, S HAEDERSDAL, J KROGH, T HANSEN, FK KNOP, ... Diabetes 71 (Supplement_1), 2022 | | 2022 |
| Individual and combined glucose-lowering effects of glucagon receptor antagonism and dipeptidyl peptidase-4 inhibition H Maagensen, S Hædersdal, A Lund, E Nielsen-Hannerup, J Holst, ... 54th Annual Meeting of the European-Association-for-the-Study-of-Diabetes …, 2018 | | 2018 |
| Role of the gut in glucose-induced suppression of bone resorption in patients with non-alcoholic fatty liver disease and/or type 2 diabetes HEG Maagensen, AE Junker, NR Jørgensen, LL Gluud, FK Knop, ... 53rd Annual Meeting of the European Association for the study of Diabetes EASD, 2017 | | 2017 |
